De novo Urothelial Carcinoma in Kidney Transplantation Patients with End-Stage Aristolochic Acid Nephropathy in China

2009 ◽  
Vol 83 (2) ◽  
pp. 200-205 ◽  
Author(s):  
Ming Yuan ◽  
Bing-Yi Shi ◽  
Han-Zhong Li ◽  
Ming Xia ◽  
Yong Han ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
Urothelial Carcinoma ◽  
Aristolochic Acid ◽  
De Novo ◽  
Aristolochic Acid Nephropathy ◽  
End Stage

scholarly journals De Novo Atypical Haemolytic Uremic Syndrome after Kidney Transplantation

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Arnaud Devresse ◽  
Martine de Meyer ◽  
Selda Aydin ◽  
Karin Dahan ◽  
Nada Kanaan
Keyword(s):  
Kidney Transplantation ◽  
De Novo ◽  
Alternative Pathway ◽  
Factor H ◽  
Complement Factor ◽  
Haemolytic Uremic Syndrome ◽  
Hinman Syndrome ◽  
Uremic Syndrome ◽  
Stage Renal Disease ◽  
End Stage

De novo thrombotic microangiopathy (TMA) can occur after kidney transplantation. An abnormality of the alternative pathway of complement must be suspected and searched for, even in presence of a secondary cause. We report the case of a 23-year-old female patient who was transplanted with a kidney from her mother for end-stage renal disease secondary to Hinman syndrome. Early after transplantation, she presented with 2 episodes of severe pyelonephritis, associated with acute kidney dysfunction and biological and histological features of TMA. Investigations of the alternative pathway of the complement system revealed atypical haemolytic uremic syndrome secondary to complement factor I mutation, associated with mutations in CD46 and complement factor H related protein genes. Plasma exchanges followed by eculizumab injections allowed improvement of kidney function without, however, normalization of creatinine.

Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy

2014 ◽  
Vol 28 (2) ◽  
pp. 199-205 ◽  
Author(s):  
Thierry Roumeguère ◽  
Nilufer Broeders ◽  
Avinash Jayaswal ◽  
Sandrine Rorive ◽  
Thierry Quackels ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Bladder Carcinoma ◽  
Aristolochic Acid ◽  
Bacillus Calmette Guerin ◽  
Aristolochic Acid Nephropathy ◽  
Muscle Invasive ◽  
End Stage

scholarly journals Immunological Characteristics and Management of Kidney Transplantation

2020 ◽  
Vol 95 (1) ◽  
pp. 18-26
Author(s):  
Myung-Gyu Kim
Keyword(s):  
Kidney Transplantation ◽  
De Novo ◽  
Treatment Strategies ◽  
Adaptive Immune System ◽  
Diagnostic Tools ◽  
Term Survival ◽  
Stage Renal Disease ◽  
End Stage ◽  
Transplant Immunology

Kidney transplantation (KT) is the best way to improve the quality of life and survival of patients with end-stage renal disease. However, after KT the adaptive immune system plays important roles in the development of rejection via multiple pathways. Accordingly, the suppression or modulation of these pathways is key to allograft survival. Advances in our understanding of the immunology related to KT with the development of immunosuppressants have reduced the rate of acute rejection and improved short-term transplant outcomes. Nonetheless, <i>de novo</i> donor-specific antibodies and subsequent chronic rejection continue to be responsible for the poor long-term survival of transplanted patients. In addition, the morbidity and mortality rates in patients returning to dialysis after graft failure are high. Better long-term outcomes following KT require innovative treatment strategies that include a focus on de novo antibodies. Here, we review basic transplant immunology as well as the diagnostic tools and medications that contribute to successful KT. We also provide an update on newly developed immunosuppressants.

Sign in / Sign up

Export Citation Format

Share Document